NasdaqGM:MNKDBiotechs
MannKind (MNKD) Stock Still Looks Cheap On Fair Value And Sales
MannKind stock has fallen 29.5% year to date, yet both an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and market based valuation multiples currently point to the shares trading at a discount to their assessed worth.
The near 30% year to date decline suggests sentiment has weakened, even as valuation models indicate potential upside from current levels.
FDA approval of Furoscix ReadyFlow may support expectations for MannKind's future revenue, while the recent US$50...